190 related articles for article (PubMed ID: 34228115)
1. Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk.
Golan Y; Prahl M; Cassidy A; Lin CY; Ahituv N; Flaherman VJ; Gaw SL
JAMA Pediatr; 2021 Oct; 175(10):1069-1071. PubMed ID: 34228115
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J
Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685
[TBL] [Abstract][Full Text] [Related]
3. Fast Development of High-Quality Vaccines in a Pandemic.
Pischel L; Yildirim I; Omer SB
Chest; 2021 Jul; 160(1):e1-e3. PubMed ID: 33848535
[No Abstract] [Full Text] [Related]
4. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.
Simone A; Herald J; Chen A; Gulati N; Shen AY; Lewin B; Lee MS
JAMA Intern Med; 2021 Dec; 181(12):1668-1670. PubMed ID: 34605853
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Wang M; Wen W; Zhou M; Wang C; Feng ZH
Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
[No Abstract] [Full Text] [Related]
6. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
[No Abstract] [Full Text] [Related]
7. Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
Liu B; Stepien S; Qian J; Gidding H; Nicolopoulos K; Amin J; Cheng A; Macartney K
Vaccine; 2023 Aug; 41(38):5587-5591. PubMed ID: 37524631
[TBL] [Abstract][Full Text] [Related]
8. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies.
Wong SY; Dixon R; Martinez Pazos V; Gnjatic S; Colombel JF; Cadwell K;
Gastroenterology; 2021 Aug; 161(2):715-718.e4. PubMed ID: 33887219
[No Abstract] [Full Text] [Related]
9. Detection of SARS-CoV-2-Specific Antibodies in Human Breast Milk and Their Neutralizing Capacity after COVID-19 Vaccination: A Systematic Review.
Nicolaidou V; Georgiou R; Christofidou M; Felekkis K; Pieri M; Papaneophytou C
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769279
[TBL] [Abstract][Full Text] [Related]
10. Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-Match.
Mulleners SJ; Juncker HG; van Gils MJ; van Goudoever JB; van Keulen BJ
J Hum Lact; 2022 Aug; 38(3):401-406. PubMed ID: 35726498
[TBL] [Abstract][Full Text] [Related]
11. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
Teo SP
J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
[TBL] [Abstract][Full Text] [Related]
12. Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021.
Young-Xu Y; Zwain GM; Powell EI; Smith J
JAMA Netw Open; 2021 Dec; 4(12):e2138975. PubMed ID: 34910155
[TBL] [Abstract][Full Text] [Related]
13. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
14. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
16. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
Zhou Z; Zhu Y; Chu M
Front Immunol; 2022; 13():898192. PubMed ID: 35669787
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
[TBL] [Abstract][Full Text] [Related]
18. Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period.
Wang L; Davis PB; Kaelber DC; Volkow ND; Xu R
JAMA; 2022 Feb; 327(7):678-680. PubMed ID: 35050314
[TBL] [Abstract][Full Text] [Related]
19. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine.
Sheng WH; Ieong SM; Lin PH; Hsieh MJ; Yang HC; Pan CF; Chao TL; Chang SY; Chang SC
J Formos Med Assoc; 2023 Feb; 122(2):121-131. PubMed ID: 36127206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
